It has been reported that P2X1 can enhance the self-renewal of LICs through PBX3-BCAT1 pathway and promote the occurrence of leukemia, and the P2X1 antagonist PPNDS can significantly reduce the proliferation of AML cells, suggesting that P2X1 may be an effective way to treat AML [20]. Here, P2RX1 is linked to acute myeloid leukemia.